Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are at least 6 years of age, and who will not have reached their 13th birthday~* Diagnosis of ADHD~* Normal intelligence~* Able to swallow capsules~Exclusion Criteria:~* Weight less than 20 kg or more than 60 kg at study entry~* Prior treatment with atomoxetine~* History of seizure disorder, suicidal risk, alcohol or drug abuse within the past 3 months~* History of severe allergies or multiple adverse drug reactions~* Cardiovascular disorders: hypertension, unexplained cardiac signs or symptoms, QT prolongation, inherited cardiac disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): 0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).